Reviews

Drug Trials and Error

  • May 2006
  • By Amanda Schaffer

Conspiracy theories about big pharma would amuse, if they were not a matter of life and death.

   

In March, Harper's magazine, ordinarily classy, bohemian, and reliably well written and reported, went ape. The venerable journal published an account of clinical drug trials that was more baleful (and more fantastic) than that painted by John le Carré in his 2000 novel The Constant Gardener, where pharmaceutical companies and governments murderously collude to hide the truth about an experimental drug.

The Harper's story, "Out of Control," by Celia Farber, is an extraordinary, overheated document. Farber is a polemicist, notorious for advancing the "Duesberg hypothesis": the argument, proposed by University of California, Berkeley, virologist Peter Duesberg, that HIV does not cause AIDS. Instead, as Farber writes in Harper's, "It could very well be the case that HIV is a harmless passenger virus that infects a small percentage of the population and is spread primarily from mother to child." Like Duesberg, Farber believes that in the United States and Europe, AIDS sufferers have poisoned themselves: "many cases of AIDS are the consequence of heavy drug use, both recreational (poppers, cocaine, methamphetamines, etc.) and medical (AZT, etc.)." In Africa, she argues, AIDS is a kind of confidence game played by pharmaceutical companies and national governments: she uncritically offers up Duesberg's position that "AIDS in Africa is best understood as an umbrella term for a number of old diseases, formerly known by other names, that...do not command high rates of international aid." Duesberg (and, we presume, Farber) consequently believes that all anti-HIV medications are poisonous shams promoted by self-serving researchers, executives, and activists: "If toxic AIDS therapies were discontinued, [Duesberg] says, thousands of lives could be saved virtually overnight."

 

To read the entire article you must log in:

Most of our content — all daily news, blogs, and videos — is free. Magazine stories are paid. To read this story, you must have a subscription or you must use a reading credit. Registration to Technology Review is free and entitles registrants to three free reading credits.

Username or REGISTER
Password  
   
 
Advertisement

MAGAZINE

Can We Build Tomorrow's Breakthroughs?

Manufacturing in the United States is in trouble. That's bad news not just for the country's economy but for the future of innovation.

Videos

Meet 2011 TR35 Winner Jesse Robbins

More

Advertisement

Technology Review Lists

TR50

Our list of the 50 most innovative companies, including the following:

Life Technologies

A123 Systems

American Superconductor

Calxeda

More

Advertisement

Facebook

Advertisement